Gilead Sciences (GILD) Tops Q4 EPS by 17c; Guides
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
February 2, 2023 4:05 PM ESTFOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys Board of Directors has declared an increase of 2.7% in the companys quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a... More
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
February 2, 2023 4:01 PM ESTProduct Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022
Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2022
Oncology Sales Increased Year-Over-Year by 71% for Full Year 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2022.
2022 marked Gileads strongest full year growth in our base business since HCV sales peaked in 2015. This return to growth was driven by consistent and high quality... More
